BERKELEY HEIGHTS, N.J., Dec. 1, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") will host a conference call on Monday, December 7 featuring Hagop M. Kantarjian, M.D., Chairman and Professor, Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. Dr. Kantarjian will review Phase 2 sapacitabine data in elderly patients with acute myeloid leukemia (AML) and older patients with myelodysplastic syndromes (MDS) to be reported at the meeting of the American Society of Hematology (ASH) on Saturday, December 5.
